Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3437-3446

  White, Kirsten L ^a   Margot, Nicolas A ^a   Wrin, Terri ^a   Petropoulos, Christos J ^a   Miller, Michael D ^a   Naeger, Lisa K ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ABACAVIR; ADENOSINE TRIPHOSPHATE; ANTIRETROVIRUS AGENT; BETA DEXTRO DIOXOLANE GUANOSINE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS ENZYME; ZIDOVUDINE;

ARTICLE; DRUG SENSITIVITY; ENZYME ANALYSIS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ADENOSINE TRIPHOSPHATE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENES, REPORTER; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IN SITU NICK-END LABELING; KINETICS; LUCIFERASES; MUTATION; PLAQUE ASSAY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; TERMINATOR REGIONS (GENETICS); VIRUS REPLICATION;

EID: 0036839746     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3437-3446.2002     Document Type: Article

References (46)

1. Arion, D., G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J. Biol. Chem. 271:19860-19864.
2. Axion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
3. Arts, E. J., X. Li, Z. Gu, L. Kleiman, M. A. Parniak, and M. A. Wainberg. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269:14672-14680.
4. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. O. Oude Essink, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
5. Bambara, R. A., P. J. Fay, and L. M. Mallaber. 1995. Methods of analyzing processivity. Methods Enzymol. 262:270-280.
6. Bazmi, H., J. Hammond, S. Cavalcanti, C. Chu, R. Schinazi, and J. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788.
7. Bloor, S., S. D. Kemp, K. Hertogs, T. Alcorn, and B. A. Larder. 2000. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12000 samples from the USA in 1999. Antivir. Ther. 5(Suppl. 3):169.
8. Boucher, C. A. B., W. Keulen, T. van Bommel, M. Nijhuis, D. de Jong, M. D. de Jong, P. Schipper, and N. K. T. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
9. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
10. Cherrington, J. M., M. D. Fuller, A. S. Mulato, S. J. W. Allen, S. C. Kunder, M. A. Ussery, Z. Lesnikowski, R. F. Schinazi, J.-P. Sommadossi, and M. S. Chen. 1996. Comparative kinetic analysis of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob. Agents Chemother. 40:1270-1273.
11. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
12. De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903.
13. Deeks, S. G., T. Wrin, T. Liegler~ R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
14. Faletto, M. B., M. W. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
15. Furman, P., J. Jeffrey, L. Kiefer, J. Feng, K. Anderson, K. Borroto-Esoda, E. Hill, W. Copeland, C. Chu, J. Sommadossi, L Liberman, R. Schinazi, and G. Painter. 2001. Mechanism of action of I-β-D-2,6-diaminopurine dioxalane, a prodrug of the human immunodeficiency virus type I inhibitor 1-β-D-dioxolane guanosine. Antimicrob. Agents Chemother. 45:158-165.
16. Gotte, M., D. Axion, M. A. Parniak, and M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:3579-3585.
17. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
18. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
19. Gu, Z., M. Wainberg, N. Nguyen-Ba, L. L'Heureux, J. De Muys, T. Bowlin, and R. Rando. 1999. Mechanism of action and in vitro activity of 1′,3′-dioxolanyipurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43:2376-2382.
20. Gu, Z., M. A. Wainberg, P. Nguyen-Ba, L. L'Heureux, J.-M. de Muys, and R. F. Rando. 1999. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dixolane. Nucleosides Nucleotides 18:891-892.
21. Hansen, J., T. Schulze, and K. Moellin. 1987. RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell tropic virus III/lymphadenopathy-associated virus. J. Biol. Chem. 262:12393-12396.
22. Harrigan, P., C. Stone, P. Griffin, I. Najera, S. Bloor, S. Kemp, M. Tisdale, and B. Larder. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. 181:912-920.
23. Hauschka, P. V. 1973, Analysis of nucleotide pools in animal cells. Methods Cell Biol. 7:361-462.
24. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
25. Kim, H., R. Schinazi, S. Nampalli, K. Shanmuganathan, D. Cannon, A. Alves, L. Jeong, J. Beach, and C. Chu. 1993. 1,3-Dioxolanylpurine nucleosides (2R.4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 36:30-37.
26. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
27. Mewshaw, J. P., F. T. Myrick, D. A. Wakefield, B. J. Hooper, J. L. Harris, B. McCreedy, and K. Borroto-Esoda. 2002. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29:11-20.
28. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:3543.
29. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
30. Miller, M. D., P. D. Lamy, M. D. Fuller, A. S. Mulato, N. A. Margot, T. Cihlar, and J. M. Cherrington. 1998. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol. Pharmacol. 54:291-297.
31. Miller, V., M. Ait-Khaled, C. Stone, P. Griffin, D. Mesogiti, A. Cutrell, R. Harrigan, S. Staszewski, C. Katlama, G. Pearce, and M. Tisdale. 2000. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14:163-171.
32. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Altered drug susceptibility of HIV-1 RT mutants containing M184V and zidovudine-resi stance mutations: analysis of RT processivity, viral replication, and chain-terminator removal. Antivir. Ther. 6:111-123.
33. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:2179-2184.
34. Naeger, L. K., and M. D. Miller. 2001. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out? Curr. Opin. Investig. Drugs 2:335-339.
35. Quan, Y., Z. Gu, X. Li, Z. Li, C. D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)-2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
36. Richman, D., and S. Staszewski. 2000. A practical guide to HIV drug resistance and its implications for antiretroviral treatment strategies, 2nd ed. International Medical Press, London, United Kingdom.
37. Sarafianos, S. G., K. Das, J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6:R137-R146.
38. Selmi, B., J. Boretto, S. R. Sarfati, C. Guerreiro, and B. Canard. 2001. Mechanism-based suppression of dideoxvnucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J. Biol. Chem. 276:48466-48472.
39. Shah, F. S., K. A. Curr, M. E. Hamburgh, M. Parniak, H. Mitsuya, J. G. Arnez, and V. R. Prasad. 2000. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 275:27037-27044.
40. Sharma, P. L., and C. S. Crumpacker. 1999. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. 73:8448-8456.
41. Siddiqui, M., W. Brown, N. Nguyen-Ba, D. Dixit, and T. Mansour. 1993. Antiviral optically pure dioxolane purine nucleoside analogs. Bioorg. Med. Chem. Lett. 3:1543-1546.
42. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
43. Traut, T. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1-22.
44. Ueno, T., and H. Mitsuya. 1997. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36:1092-1099.
45. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA, Antivir. Ther. 4:87-94.
46. Wilson, J. E., A. Aulabaugh, B. Caligan, S. McPherson, J. K. Wakefield, S. Jablonski, C. D. Morrow, J. E. Reardon, and P. A. Furman. 1996. Human Immunodeficiency virus type-1 reverse transcriptase contribution of Met-184 to binding of nucleoside 5′-triphosphate. J. Biol. Chem. 271:13656-13662.